Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 40
- Registration Number
- NCT06163391
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇧🇪Universitair Ziekenhuis Antwerpen (UZA), Edegem, Antwerp, Belgium
🇧🇪Institut Jules Bordet, Anderlecht, Brussels, Belgium
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 16
- Registration Number
- NCT05619172
- Locations
- 🇧🇪
Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇫🇷Institut Bergonié, Bordeaux, France
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
- Conditions
- Colorectal CancerCastration-resistant Prostate CancerOvarian CancerHepatocellular CarcinomaNon-Small Cell Lung CancerCutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 166
- Registration Number
- NCT05256381
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸University of Pittsburg Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
- Conditions
- MelanomaThyroid CancerRenal Cell CarcinomaNon Small Cell Lung CancerSmall-cell Lung CancerBladder CancerMerkel Cell CarcinomaSkin Squamous Cell CarcinomaMicrosatellite Instability HighTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 115
- Registration Number
- NCT04234113
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States